Consultation and knowledge translation in laboratory medicine;La consulenza e la Knowledge Translation in medicina di laboratorio

Rivista Italiana della Medicina di Laboratorio

Volumn 1, Issue SUPPL. 3, 2005, Pages 60-71

  Dorizzi, Romolo M ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL LABORATORY; CLINICAL MEDICINE; CLINICAL PRACTICE; COMPUTER PROGRAM; CONFERENCE PAPER; CONSULTATION; DIAGNOSTIC PROCEDURE; HEALTH CARE; INFORMATION PROCESSING; INFORMATION TECHNOLOGY; KNOWLEDGE; MASS MEDIUM; MEDICAL INFORMATION;

EID: 33747751918     PISSN: 1825859X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Institute of Medicine. Crossing the quality chasm: a new health system for the 21th century. Washington, DC: National Academy Press; 2001.
2. Berwick DM. Dissemination of innovations in health care. JAMA 2003; 289: 1969-75.
3. Fisher ES, Wennberg DE, Stukel TA, Gottlieb PJ, Lucas FL, Pinder EL. The implications of regional variations in medicare spending. Part I: the content, quality and accessibility of care. Ann Intern Med 2003; 138: 273-87.
4. Fisher ES, Wennberg DE, Stukel TA, Gottlieb PJ, Lucas FL, Pinder EL. The implications of regional variations in medicare spending. Part II: health outcomes and satisfaction with care. Ann Intern Med 2003; 138: 288-98.
5. Rogers EM. Diffusion of Innovations. New York: Free Press;1995.
6. Meyer AD, Goes JB. Organizational assimilation of innovations: a multilevel contextual analysis. Acad Manag J 1998; 31: 897-923.
7. Lenfant C. Clinical Research to Clinical Practice-Lost in Translation? N Engl J Med 2003; 349: 868-74.
8. http://nihroadmap.nih.gov/initiatives.asp (data di consultazione: 26.08.2005).
9. http://www.cihr-irsc.gc.ca/e/22985.html (datadi consultazione: 26.08.2005).
10. http://www.medicine.uottawa.ca/epid/eng/grimshawbio.html (data di consultazione: 26.08.2005).
11. Grol R, Grimshaw J. From best evidence to best care: effective implementation of change in patients' care. Lancet 2003; 362: 125-30.
12. Jain A, Atreja A, Harris CM, Lehmann M, Burns J, Young J. Responding to the Rofecoxib withdrawal crisis: a new model for notifying patients at risk and their health care providers. Ann Intern Med 2005; 142: 182-6.
13. Badgett R, Mulrow C. Using Information Technology to transfer knowledge: a medical institution steps up to the plate. Ann Intern Med 2005; 142: 220-1.
14. Roumie CL, Grogan EL, Falbe W, Awad J, Speroff T, Dittus RS, et al. Three-part intervention to change the use of hormone replacement therapy in response to new evidence. Ann Intern Med 2004; 141: 118-25.
15. The Lewin Group. The value of diagnostics innovation. Adoption and diffusion in Health Care. Washington: AdvaMed; 2005.
16. Berwick DM. A user's manual for the IOM's "Quality Chasm" report. Health Affairs 2001; 21: 80-90.
17. Davis D, Evans M, Jadad A, Perrier L, Rath D, Ryan D, et al. The case for knowledge translation: shortening the journey from evidence to effect. BMJ 2003; 327: 33-35.
18. Greenhalgh T, Glenn R, Macfarlan F, Bate P, Kyriakidou O. Diffusion of innovations: systematic review and recommendation. Millbank Quaterly 2004; 82: 581-624.
19. Crist TB, Schafer AI, Walsh RA. Translating basic discovery into better health care: the APM's recommendations for improving translational research. Am J Med 2004; 116: 431-4.
20. Ioannidis JPA. Contradicted and initially stronger effects in highly cited clinical reserach. JAMA 2005; 294: 218-20.
21. Cole LA, Sutton JM, Higgins TN Cembrowski GS. Between-method variation in human chorionic gonadotropin test results. Clin Chem 2004; 50: 874-82.
22. Stenman UH. Standardization of assays for human chorionic gonadotropin. Clin Chem 2004; 50: 790-800.
23. Stenman UH. Immunoassay standardization: is it possible, who is responsible, who is capable? Clin Chem 2001; 47: 815-820.
24. Bristow A, Berger P, Bidart JM, Birken S, Norman R, Stenman UH, et al. Establishment, value assignment, and characterization of new who reference reagents for six molecular forms of human chorionic gonadotropin. Clin Chem 2005; 51: 177-82.
25. Klee GG, Hay ID. Role of thyrotropin measurements in the diagnosis and management of thyroid disease. Clin Lab Med 1999; 13: 673-82.
26. http://www.nacb.org/lmpg/thyroid/3c_thyroid.pdf (data di consultazione: 26.08.2005).
27. Col NF, Surks MI, Daniels GH. Subclinical thyroid disease. Clinical applications. JAMA 2004; 291: 239-43.
28. Surks MI, Ortiz E, Daniels GH, Sawin CH, Col NF, Cobin RH. Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228-38.
29. Helfand M. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140: 12-141.
30. http://www.nacb.org/lmpg/tumor/chp2_qreqs.pdf (data di consultazione: 26.08.2005)
31. http://www.ospedaliverona.it/octopus/documenti/unitaoperative/ TabellalU1marzo05.pdf (data di consultazione: 26.08.2005)
32. Dorizzi RM, Giavarina D, Fosser V, Fortunato A, Soffiati G, Rizzotti P. Appunti per Linee guida Evidence-Based per la richiesta, l'esecuzione, la refertazione degli indicatori biochimici di cancro (marcatori tumorali, biomarcatori). RML 2004; 5: 219-24.
33. Gibney JG, Smith TP, McKenna J Clinical relevance of macroprolactin. Clin Endocrinol 2005; 62: 633-43.
34. Fahie-Wilson MN, John R, Ellis AR. Macroprolactin; high molecular mass forms of circulating prolactin. Ann Clin Biochem 2005; 42: 175-92.
35. Marcolla A, Dilberis C, Dal Bosco F, Amadori F. Impatto clinico e laboratoristico delle isoforme macromolecolari della prolattina. RIMeL-IJLM 2005; 1: 123-9.
36. Dorizzi RM, Castello R, Moghetti P. Sorting the wheat from the chaff in macroprolactinemia assessment. Ann Clin Biochem 2005; 42 (in press).
37. Dorizzi RM. Il TDM nelle malattie cardiache è "evidence based"? RIMeL-IJLM 2005; 1: 69-83.
38. Dorizzi RM. Appropriatezza diagnostica: gli strumenti per misurare. RML-JLM 2004; 5: 123-9.
39. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-84.
40. Eastham JA, Riedel E, Scardino PT, Shike M, Fleisher M, Schatzkin A, et al. Variations of serum prostate-specific antigen levels; an evaluation of year-to-year fluctuations. JAMA 2003: 289: 2695-700.
41. McNaughton-Collins M, Fowler FJ, Caubet JF, Bates DW, Lee JM, Hauser A, et al. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. Am J Med 2004; 117: 719-25.
42. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level <= 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-246.
43. U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: Recommendations from the U.S. Preventive Services Task Force. Ann Intern Med 2005; 142: 855-60.
44. Dorizzi RM. Foraging, andare per foraggio (cercare le informazioni che ci servono) sulla rete. RIMeL-IJLM 2005; 1: 165-6.
45. Dorizzi RM, Esposito E. Dalle specifiche di qualità allo STARD. RML-JLM 2004; 5(S3): 89-95.